Cite

HARVARD Citation

    Fine, S. et al. (n.d.). S780 Outcomes for Patients With IBD and Discontinuation of Biologic Therapy Due to Primary vs SLR and Then Treated With Ustekinumab. American journal of gastroenterology. p. S361. [Online]. 
  
Back to record